Healthcare, Prescription Drugs and Medicare filing activity was distributed across 4 reviewed organizations, with no single organization accounting for half of the matches.
19 retained filings matched this issue group. Pfizer had the largest count at 8 (42%), and 4 organizations appeared in both quarters.
Evidence and reasoning
Reasoning: Gov Influence uses a transparent majority threshold: one organization must account for at least 50% of matched filings for the pattern to be called concentrated. The leading share is 42%; recurrence across both comparable quarters helps distinguish a sustained collection pattern from a single-quarter cluster. These measures describe filing distribution, not political importance, position, effort, or influence.
Scope: 2026 Q1–Q2, within the reviewed Gov Influence collection for Healthcare, Prescription Drugs and Medicare.
Other plausible interpretation
- Quarterly filing cadence, organization reporting structure, and the breadth of the official issue codes may shape the distribution; the selected six-organization, two-quarter collection does not establish a longer-term or Washington-wide pattern.
Method: issue-profile-assessment-v1
Editorial review: Gov Influence editorial review; Sep 8, 2026
- Lobbying disclosure
10119e1b-77e7-4537-ab88-f4ecb8439048 - Lobbying disclosure
17640998-df82-47e3-8ad7-0afe51148524 - Lobbying disclosure
1931ae85-b9ac-4300-a80a-f8879982563b - Lobbying disclosure
2cc79e15-9bc4-4964-8548-7e08d69a08b5 - Lobbying disclosure
56623a9e-574f-4fdc-946d-f356a2aa3da6 - Lobbying disclosure
58be6f34-3d49-47c5-b374-344da1198e80 - Lobbying disclosure
5999e679-18fd-4dca-aae9-a9ccee3f0238 - Lobbying disclosure
5e947cad-7bb7-4291-bb48-85856b0c8c27 - Lobbying disclosure
829ee548-f839-48f3-b637-84f57c41a4c0 - Lobbying disclosure
8f2443e8-3a53-4dc9-b865-a33dae4bc86e - Lobbying disclosure
9cdc8552-13e7-4a50-83eb-10376b07ab0e - Lobbying disclosure
9e38acf4-31e2-4028-9861-7a2134485aac - Lobbying disclosure
9f6571d0-ce12-4a99-8d34-ea989b315952 - Lobbying disclosure
b4893a31-d047-4ff4-be33-fede34eb8860 - Lobbying disclosure
dd2425d1-a5b8-44b3-8e63-c481f0bce531 - Lobbying disclosure
dd31025d-92a7-4fb3-87ab-b3fc6ae1d498 - Lobbying disclosure
eb88d053-1e97-4089-8e38-d2234c9bb80e - Lobbying disclosure
fbad5885-a4be-4f7d-a3d3-41b2386ef55d - Lobbying disclosure
fd396ae2-9ccb-406c-9d41-c8da6996906e
